Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Hepatology

Building a Long-Term Plan: Prognosis and Survivorship

At a Glance

An episode of overt hepatic encephalopathy (OHE) indicates significant liver disease progression. The most critical steps for long-term survival include starting a liver transplant evaluation, managing muscle loss through nutrition, and carefully monitoring for recurring symptoms.

Facing a diagnosis of Overt Hepatic Encephalopathy (OHE) is a turning point in the management of liver disease. It is a sign that the liver is no longer able to keep up with its filtration duties, making it a critical marker of the disease’s progression [1]. While the symptoms themselves are manageable, the long-term outlook requires a shift in focus toward survivorship, nutrition, and potential transplantation.

Understanding the Long-Term Outlook

An episode of Overt HE is what doctors call a “decompensating event.” It is a serious indicator that the liver is struggling significantly. Statistically, patients who experience an OHE episode have a lower “transplant-free” survival rate over the following year compared to those who have not [2]. Frequent recurrences of these episodes further increase the risk to a patient’s health and longevity [3].

Because of these risks, the standard medical recommendation after even one episode of Overt HE is to begin a liver transplant evaluation [4]. While medications like lactulose and rifaximin are excellent at managing symptoms and preventing hospital stays, a liver transplant is currently the only definitive way to address the underlying liver failure [5].

The Power of Muscle: Fighting Sarcopenia

You or your loved one may notice losing weight or looking “frail” in the arms and legs, even if the abdomen is swollen. This loss of muscle mass is called sarcopenia, and it is one of the most significant risk factors for HE [6].

When the liver is failing, your body’s muscles step in as a “backup filter” to help process and clear ammonia from the blood [7]. If muscle mass is lost, this backup system disappears, leading to higher levels of toxins reaching the brain and more frequent HE flare-ups [8]. Protecting and building muscle through specialized nutrition and safe exercise is a vital, but often overlooked, part of long-term HE management [9].

The “Double-Edged Sword” of TIPS

Some patients with cirrhosis undergo a procedure called TIPS (Transjugular Intrahepatic Portosystemic Shunt). This is a stent placed in the liver to reduce high blood pressure in the veins and prevent internal bleeding [10].

While TIPS is life-saving for some, it can be a “double-edged sword” for HE. Because the stent creates a “shortcut” for blood to bypass the liver, more unfiltered toxins—including ammonia—can head straight to the brain [11]. Up to half of all patients may experience new or worsening HE after a TIPS procedure, particularly those who already have significant muscle loss [12][13].

Steps for the Journey Ahead

Managing HE over the long term is a marathon, not a sprint. Success depends on a combination of medical intervention and daily care:

  • Transplant Evaluation: Discussing a transplant early ensures that you are in the system if the condition worsens [4].
  • Nutritional Support: High-protein diets (under medical supervision) are often used to fight muscle wasting and help the body manage toxins [8].
  • Vigilant Monitoring: Keeping a close eye on bowel movements and mental clarity can catch a flare-up before it becomes an emergency [14].

While the road ahead is challenging, being proactive about nutrition and transplant discussions can help you navigate this diagnosis with a sense of control and purpose.

Common questions in this guide

Why do I need a liver transplant evaluation after an HE episode?
An episode of overt hepatic encephalopathy is a sign that your liver is severely struggling to filter toxins. While medications can manage your symptoms, a liver transplant is currently the only definitive way to cure the underlying liver failure.
How does muscle loss affect hepatic encephalopathy?
When your liver is failing, your muscles act as a backup filter to help clear ammonia from your blood. Losing muscle mass, a condition called sarcopenia, removes this backup system and allows higher levels of toxins to reach your brain, leading to more frequent HE flare-ups.
Can a high-protein diet help manage hepatic encephalopathy?
Yes, supervised high-protein diets are often recommended to fight muscle wasting in patients with severe liver disease. Maintaining your muscle mass gives your body a better chance at filtering ammonia and managing toxins safely.
Will a TIPS procedure increase my risk for confusion?
While a TIPS procedure reduces pressure in liver veins, it creates a shortcut that allows unfiltered blood to bypass the liver completely. Because more ammonia reaches the brain, up to half of patients may experience new or worsening confusion after the procedure.
What does a decompensating event mean for my prognosis?
A decompensating event is a critical medical milestone indicating that your liver can no longer keep up with its essential functions. Experiencing one means your long-term medical strategy must shift toward survivorship, strict nutrition, and potential transplantation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the history of an overt HE episode, can we begin the referral process for a liver transplant evaluation?
  2. 2.How severe is the sarcopenia (muscle loss), and can we work with a dietitian to create a high-protein nutrition plan to help the muscles clear ammonia?
  3. 3.If we are considering a TIPS procedure for other complications, how much will it increase the risk of confusion returning?
  4. 4.What is the current MELD score (Model for End-Stage Liver Disease), and how has the HE episode changed the overall prognosis?
  5. 5.Are there specific exercises or physical therapies that are safe to do to help rebuild or maintain muscle mass?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Inpatient Hepatology Consultation: A Practical Approach for Clinicians.

    Díaz LA, Pages J, Mainardi V, Mendizabal M

    The Medical clinics of North America 2023; (107(3)):555-565 doi:10.1016/j.mcna.2023.01.006.

    PMID: 37001953
  2. 2

    Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis.

    Desplats V, Haudebourg L, Verger N, et al.

    Hepatology (Baltimore, Md.) 2025; (82(6)):1480-1497 doi:10.1097/HEP.0000000000001252.

    PMID: 39879584
  3. 3

    Early-Recurrent Overt Hepatic Encephalopathy Is Associated with Reduced Survival in Cirrhotic Patients after Transjugular Intrahepatic Portosystemic Shunt Creation.

    Zuo L, Lv Y, Wang Q, et al.

    Journal of vascular and interventional radiology : JVIR 2019; (30(2)):148-153.e2 doi:10.1016/j.jvir.2018.08.023.

    PMID: 30638778
  4. 4

    Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.

    Bohra A, Worland T, Hui S, et al.

    World journal of gastroenterology 2020; (26(18)):2221-2231 doi:10.3748/wjg.v26.i18.2221.

    PMID: 32476788
  5. 5

    Investigation of Post-Transplant Mental Well-Being in Liver Transplant Recipients with Hepatic Encephalopathy.

    Saritaş S, Tarlaci S, Bulbuloglu S, Guneş H

    Journal of clinical medicine 2024; (13(11)) doi:10.3390/jcm13113249.

    PMID: 38892960
  6. 6

    The Utility of Psoas Muscle Index for the Detection of Sarcopenia and its Association with Severity of Alcoholic Liver Cirrhosis: Western India Perspective.

    Pandya KJ, Pathak JM, Judal HP, Patel AM

    The Journal of the Association of Physicians of India 2025; (73(1)):e1-e7 doi:10.59556/japi.73.0809.

    PMID: 39893523
  7. 7

    Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement.

    Nardelli S, Lattanzi B, Torrisi S, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2017; (15(6)):934-936 doi:10.1016/j.cgh.2016.10.028.

    PMID: 27816756
  8. 8

    Attenuating hyperammonemia preserves protein synthesis and muscle mass via restoration of perturbed metabolic pathways in bile duct-ligated rats.

    Bosoi CR, Kumar A, Oliveira MM, et al.

    Metabolic brain disease 2025; (40(1)):110 doi:10.1007/s11011-024-01525-2.

    PMID: 39847228
  9. 9

    Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial.

    Bruno BJ, Weavil JC, Ogle J, et al.

    Hepatology (Baltimore, Md.) 2025; (81(6)):1764-1775 doi:10.1097/HEP.0000000000001146.

    PMID: 39513970
  10. 10

    Overt hepatic encephalopathy after elective and preemptive TIPS: Risk factors and prognosis.

    Rudler M, Bouzbib C, Sultanik P, et al.

    JHEP reports : innovation in hepatology 2025; (7(11)):101548 doi:10.1016/j.jhepr.2025.101548.

    PMID: 41159057
  11. 11

    Research status and hotspots in transjugular intrahepatic portosystemic shunts based on CiteSpace bibliometric analysis.

    Que ZL, Wu MS, Lai SJ, et al.

    World journal of gastrointestinal surgery 2024; (16(9)):2996-3007 doi:10.4240/wjgs.v16.i9.2996.

    PMID: 39351573
  12. 12

    Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy: Sarcopenia Adds Insult to Injury.

    Bhatia Kapoor P, Benjamin J, Tripathi H, et al.

    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2023; (34(4)):406-412 doi:10.5152/tjg.2023.21964.

    PMID: 36620928
  13. 13

    Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt.

    Yin L, Chu SL, Lv WF, et al.

    World journal of gastroenterology 2023; (29(18)):2875-2887 doi:10.3748/wjg.v29.i18.2875.

    PMID: 37274064
  14. 14

    Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list.

    Salehi S, Tranah TH, Lim S, et al.

    Alimentary pharmacology & therapeutics 2019; (50(4)):435-441 doi:10.1111/apt.15326.

    PMID: 31169941

This page provides educational information about hepatic encephalopathy prognosis and long-term care. It does not replace professional medical advice, and you should always consult your hepatologist regarding transplant evaluations, diet changes, and treatment plans.

Get notified when new evidence is published on Hepatic Encephalopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.